Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug development

Godoy-Matos, A. F., Silva Júnior, W. S. & Valerio, C. M. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol. Metab. Syndr. https://doi.org/10.1186/s13098-020-00570-y (2020).Article 
PubMed 
PubMed Central 

Google Scholar 
Schuster, S., Cabrera, D., Arrese, M. & Feldstein, A. E. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349–364. https://doi.org/10.1038/s41575-018-0009-6 (2018).Article 
CAS 
PubMed 

Google Scholar 
Zhu, C., Tabas, I., Schwabe, R. F. & Pajvani, U. B. Maladaptive regeneration—the reawakening of developmental pathways in NASH and fibrosis. Nat. Rev. Gastroenterol. Hepatol. 18, 131–142. https://doi.org/10.1038/s41575-020-00365-6 (2021).Article 
PubMed 

Google Scholar 
Schonmann, Y., Yeshua, H., Bentov, I. & Zelber-Sagi, S. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig. Liver Dis. 53, 79–85 (2021).Article 
CAS 
PubMed 

Google Scholar 
Vieira Barbosa, J. et al. Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD. Hepatol. Commun. 6, 2022 (2021).
Google Scholar 
Keam, S. J. Resmetirom: First approval. Drugs 84, 729–735 (2024).Article 
CAS 
PubMed 

Google Scholar 
Stiglund, N., Hagström, H., Stål, P., Cornillet, M. & Björkström, N. K. Dysregulated peripheral proteome reveals NASH-specific signatures identifying patient subgroups with distinct liver biology. Front. Immunol. 14, 1186097 (2023).Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 
Jorge, A. S. B. et al. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obes. Res. Clin. Pract. 12, 1–8 (2018).Article 
PubMed 

Google Scholar 
Adolph, T. E., Grander, C., Grabherr, F. & Tilg, H. Adipokines and non-alcoholic fatty liver disease: Multiple interactions. Int. J. Mol. Sci. https://doi.org/10.3390/ijms18081649 (2017).Article 
PubMed 
PubMed Central 

Google Scholar 
Kisseleva, T. & Brenner, D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18, 151–166. https://doi.org/10.1038/s41575-020-00372-7 (2021).Article 
PubMed 

Google Scholar 
Arrese, M. et al. Insights into nonalcoholic fatty-liver disease heterogeneity. Semin. Liver Dis. 41, 421–434. https://doi.org/10.1055/s-0041-1730927 (2021).Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 
Suppli, M. P. et al. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. Am. J. Physiol. Gastrointest. Liver Physiol. 316, 462–472 (2019).Article 

Google Scholar 
Martínez-Arranz, I. et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology 76, 1121–1134 (2022).Article 
PubMed 

Google Scholar 
Ratziu, V. & Friedman, S. L. Why do so many NASH trials fail?. Gastroenterologyhttps://doi.org/10.1053/j.gastro.2020.05.046 (2020).Article 
PubMed 

Google Scholar 
Guan, Y. et al. Characterization of pro-fibrotic signaling pathways using human hepatic organoids. https://doi.org/10.1101/2023.04.25.538102.Alonso, C., Noureddin, M., Lu, S. C. & Mato, J. M. Biomarkers and subtypes of deranged lipid metabolism in nonalcoholic fatty liver disease. World J. Gastroenterol. 25, 3009–3020. https://doi.org/10.3748/wjg.v25.i24.3009 (2019).Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 
Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361 (2018).Article 
PubMed 

Google Scholar 
Govaere, O. et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci. Transl. Med. 12http://stm.sciencemag.org/ (2020).Hoang, S. A. et al. Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease. Sci. Rep. 9, 12541 (2019).Article 
ADS 
PubMed 
PubMed Central 

Google Scholar 
Verschuren, L. et al. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. Nat. Commun. 15, 4564 (2024).Article 
ADS 
CAS 
PubMed 
PubMed Central 

Google Scholar 
Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform. 9, 1–13 (2008).Article 

Google Scholar 
Package ‘Pheatmap’ (2022).Liu, H. et al. Entropy-based consensus clustering for patient stratification. Bioinformatics 33, 2691–2698 (2017).Article 
CAS 
PubMed 

Google Scholar 
Brooks-Warburton, J. et al. A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis. Nat. Commun. 13, 2299 (2022).Article 
ADS 
CAS 
PubMed 
PubMed Central 

Google Scholar 
Shu, Z. et al. Symptom-based network classification identifies distinct clinical subgroups of liver diseases with common molecular pathways. Comput. Methods Programs Biomed. 174, 41–50 (2019).Article 
PubMed 

Google Scholar 
Li, L. et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity. https://www.science.org.Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1–21 (2014).Article 

Google Scholar 
Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. SMOTE: Synthetic minority over-sampling technique. J. Artif. Intell. Res. 16, 321–357 (2002).Article 

Google Scholar 
He, H., Bai, Y., Garcia, E. A. & Li, S. ADASYN: Adaptive synthetic sampling approach for imbalanced learning. In Proceedings of the International Joint Conference on Neural Networks 1322–1328 (2008). https://doi.org/10.1109/IJCNN.2008.4633969.Lemaitre, G., Nogueira, F. & Aridas, C. K. Imbalanced-learn: A Python toolbox to tackle the curse of imbalanced datasets in machine learning (2016).Pedregosa, F. et al. Scikit-learn: Machine learning in Python (2012).Marschner, I., Donoghoe, M. W., glm2: Fitting Generalized Linear Models, R package version 1.2.1, https://cran.rproject.org/web/packages/glm2/index.html (2022).Ampuero, J. & Romero-Gomez, M. Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Rep. https://doi.org/10.1016/j.jhepr.2020.100148 (2020).Article 
PubMed 
PubMed Central 

Google Scholar 
Arguello, G., Balboa, E., Arrese, M. & Zanlungo, S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta Molecular Basis of Disease 1852, 1765–1778. https://doi.org/10.1016/j.bbadis.2015.05.015 (2015).Article 
CAS 

Google Scholar 
Steinberg, G. R. & Hardie, D. G. New insights into activation and function of the AMPK. Nat. Rev. Mol. Cell Biol.https://doi.org/10.1038/s41580-022-00547-x (2022).Article 
PubMed 

Google Scholar 
Gerhard, G. S. et al. AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372–3p. PLoS One 14, e0219764 (2019).Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 
Wang, Z. Y. et al. Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis. Sci. Rep. 11, 19396 (2021).Article 
ADS 
CAS 
PubMed 
PubMed Central 

Google Scholar